



# Analisi e presentazione dati (C. Buzzoni<sup>1,2</sup>, D. Mirabelli<sup>3</sup>)

1 ISPO, Firenze

2 Banca Dati AIRTUM

3 CPO Piemonte e Registro Mesoteliomi Maligni del Piemonte



## Workshop AIRTUM-RENAM

### Come registrare i mesoteliomi ed analizzare i dati

Reggio Emilia, 23 settembre 2016

Sede: Palazzo Rocca Saporiti, Viale Murri 7



# Associazione Italiana Registri Tumori

HOME CERCA CHI SIAMO CONVEGNI AIRTUM REDAZIONE PRIVACY STAMPA

Nome utente: \*  
Password: \*  
Accedi

[Richiedi nuova password](#)

Home

## Monografie AIRTUM

I Tumori in Italia - Rapporto 2015  
I tumori rari in Italia  
(pubblicato a febbraio 2016)

I Tumori in Italia - Rapporto 2014  
Prevalenza e guarigione da tumore in Italia  
(pubblicato a febbraio 2015)

I Tumori in Italia - Rapporto 2013  
Tumori multipli  
(pubblicato a novembre 2013)

I Tumori in Italia - Rapporto 2012  
I tumori dei bambini e degli adolescenti  
(pubblicato a marzo 2013)

> Home Page

> I Registri tumori

> AIRTUM

> Numeri come  
Notizie

> Banca Dati AIRTUM

> Progetti AIRTUM

> Formazione

> Pubblicazioni **NEW**

• Anticipazioni

• Monografie AIRTUM

• Manuali

• Collaborazioni

## In primo piano

Corso AIRTUM per operatori dei RT  
12-13 ottobre 2016  
Salerno



Programma e scheda d'iscrizione del corso "Come registrare i mesoteliomi ed analizzare i dati

23 settembre 2016,  
Reggio Emilia

Il nuovo corso  
FAD AIRTUM 2016



# RARE EPITHELIAL TUMOURS OF THE THORACIC CAVITY



I tumori in Italia • Rapporto AIRTUM 2015

# INCIDENCE

**RARE EPITHELIAL TUMOURS OF THE THORACIC CAVITY.** Crude incidence (rate per 100,000/year) and 95% confidence interval (95% CI), observed cases and proportion of rare cancers on all (common + rare) cancers by site. Rates with 95% CI by sex and age. Estimated new cases at 2015 in Italy.



	AIRTUM POOL (period of diagnosis 2000-2010)												ESTIMATED NEW CASES 2015		
	OBSERVED CASES (No.)		RARE CANCERS BY SITE (%)	SEX			AGE								
	RATE	95% CI		MALE		FEMALE		0-54 yrs		55-64 yrs		65+ yrs			
			RATE	95% CI	RATE	95% CI	RATE	95% CI	RATE	95% CI	RATE	95% CI			
<b>RARE EPITHELIAL TUMOURS OF THE THORACIC CAVITY</b>	5.42	5.33-5.52	12 027	8%	8.57	8.39-8.74	2.48	2.39-2.57	0.87	0.82-0.92	10.14	9.77-10.53	18.08	17.69-18.49	3 590
<b>EPITHELIAL TUMOURS OF TRACHEA</b>	0.17	0.15-0.19	374	95%	0.27	0.24-0.30	0.07	0.06-0.09	0.03	0.02-0.04	0.33	0.27-0.41	0.55	0.48-0.62	113
Squamous cell carcinoma with variants of trachea	0.08	0.07-0.09	175		0.14	0.11-0.16	0.03	0.02-0.04	0.01	0.01-0.02	0.16	0.12-0.22	0.26	0.21-0.31	53
Adenocarcinoma with variants of trachea	0.03	0.02-0.04	64		0.05	0.04-0.06	0.01	0.01-0.02	<0.01	0.00-0.01	0.08	0.05-0.12	0.03	0.06-0.11	19
Salivary gland type tumours of trachea	0.01	0.01-0.02	26		0.01	0.01-0.02	0.01	0.01-0.02	<0.01	0.00-0.01	0.02	0.01-0.04	0.03	0.02-0.05	8
<b>RARE EPITHELIAL TUMOURS OF LUNG</b>	2.58	2.51-2.65	5 722	4%	4.37	4.24-4.49	0.91	0.85-0.96	0.40	0.36-0.43	4.97	4.71-5.25	8.57	8.30-8.85	1 699
Adenosquamous carcinoma of lung	0.41	0.38-0.44	909		0.66	0.61-0.71	0.18	0.15-0.20	0.06	0.05-0.08	0.76	0.66-0.87	1.39	1.28-1.50	268
Large cell carcinoma of lung	1.84	1.78-1.89	4 071		3.18	3.07-3.29	0.58	0.54-0.62	0.26	0.23-0.28	3.53	3.31-3.76	6.20	5.97-6.43	1 213
Salivary gland type tumours of lung	0.06	0.05-0.07	140		0.09	0.07-0.11	0.04	0.03-0.05	0.03	0.02-0.04	0.12	0.09-0.17	0.15	0.11-0.19	41
Sarcomatoid carcinoma of lung	0.27	0.25-0.29	602		0.44	0.40-0.48	0.11	0.09-0.13	0.05	0.04-0.06	0.56	0.48-0.66	0.85	0.76-0.94	177
<b>EPITHELIAL TUMOURS OF THYRUS</b>	0.36	0.34-0.39	804	97%	0.41	0.38-0.45	0.32	0.28-0.35	0.18	0.16-0.20	0.73	0.64-0.84	0.75	0.67-0.84	232
Malignant thymoma	0.28	0.25-0.30	612		0.31	0.28-0.35	0.24	0.21-0.27	0.15	0.13-0.17	0.56	0.47-0.65	0.54	0.47-0.61	175
Squamous cell carcinoma of thymus	0.02	0.02-0.03	46		0.02	0.02-0.03	0.02	0.01-0.03	<0.01	0.00-0.01	0.06	0.04-0.10	0.05	0.03-0.08	13
Undifferentiated carcinoma of thymus	<0.01	0.00-0.01	9		NE	—	NE	—	NE	—	NE	—	NE	—	2
Lymphoepithelial carcinoma of thymus	<0.01	0.00-0.01	6		NE	—	NE	—	NE	—	NE	—	NE	—	2
Adenocarcinoma with variants of thymus	<0.01	0.00-0.01	7		NE	—	NE	—	NE	—	NE	—	NE	—	2
<b>MESOTHELIOMA OF PLEURA AND PERICARDIUM</b>	2.31	2.25-2.38	5 127	74%	3.51	3.40-3.63	1.19	1.12-1.25	0.27						



SOURCE: AIRTUM, ITALIAN CANCER FIGURES-REPORT 2015



Pool of Italian Cancer Registries - 1 January 2010

## MESOTELIOMA MESOTHELIOMA (ICD-10 C45)


### COMPLETE PREVALENCE BY YEARS SINCE DIAGNOSIS

YEARS →	≤ 2	(2-5]	(5-10]	(10-15]	(15-20]	> 20
No. →	1 595	558	241	123	96	119
% →	58%	20%	9%	4%	4%	4%
PROPORTION → PER 100,000	2.9	1.0	0.5	0.2	0.1	0.3
	<b>MALE 71%</b>					<b>FEMALE 29%</b>

### COMPLETE PREVALENCE BY SEX, MACRO-AREA, AND AGE (PROPORTION PER 100,000)

AGE CLASS →	0-44	45-59	60-74	75+	ALL AGES
<b>MALE</b>					
NORTH WEST	1	6	25	48	10
NORTH EAST	0	5	28	22	8
CENTRE	0	5	14	20	5
SOUTH	0	7	16	18	5
POOL	0	6	23	29	7
<b>FEMALE</b>					
NORTH WEST	0	5	12	13	5
NORTH EAST	0	1	8	6	3
CENTRE	0	2	3	0	1
SOUTH	0	1	6	2	1
POOL	0	2	8	7	3
<b>BOTH SEXES</b>					
NORTH WEST	0	5	18	26	8
NORTH EAST	0	3	18	12	5
CENTRE	0	3	8	8	3
SOUTH	0	4	11	8	3
POOL	0	4	15	15	5

### COMPLETE PREVALENCE AND PROPORTION OF ALREADY CURED SURVIVORS BY SEX



### CURE FRACTION AND TIME TO CURE BY AGE AT DIAGNOSIS AND SEX FOR CANCER PATIENTS DIAGNOSED IN ITALY IN 1985-2009


AGE AT DIAGNOSIS	CURE FRACTION %	
	MALE	FEMALE
0-44	15%	21%
45-59	7%	11%
60-74	2%	5%
75+	1%	2%

AGE AT DIAGNOSIS	TIME TO CURE YEARS	
	MALE	FEMALE
0-44	6	6
45-59	6	6
60-74	6	6
75+	6	6

2 587 347 CANCER SURVIVORS

2 732  
MESOTHELIOMA  
CANCER SURVIVORS

ALREADY CURED  
at 1 JANUARY 2010  
453 (17%)



**COMPLETE PREVALENCE**  
Overall number (or proportion) of cancer survivors.

**TIME TO CURE**  
Time soon after cancer diagnosis necessary to eliminate excess mortality due to cancer. It is measured as the time necessary to reach a 5-year conditional relative survival (that is the probability to survive additional five years) >95%.

**ALREADY CURED SURVIVORS**  
Patients who have survived longer than time to cure.

**CURE FRACTION**  
Proportion of cancer patients who are expected to reach the same death rates as the general population and will not die as a result of their cancer.



6  
ANNO  
NUMERO

# EPIDEMIOLOGIA & PREVENZIONE

Rivista dell'Associazione italiana di epidemiologia

AIRTUM Working group

ITUMORI IN ITALIA - RAPPORTO 2014

## Prevalenza e guarigione da tumore in Italia

ITALIAN CANCER FIGURES - REPORT 2014

## Prevalence and cure of cancer in Italy



**FIRST CANCER SITE**  
**MESOTHELIOMA**

Number of subjects alive at the beginning of the interval, person-years at risk (PY), number of Observed (O) second cancers, Standardized Incidence Ratio (SIR) and Excess Absolute Risk (EAR) x 1000 cancer patients by second cancer site and follow-up period.

SECOND CANCER SITE	>2 months		12-59 months		60-119 months		>120 months		>2 months		>2 months	
	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	EAR	EAR
ALL SITES, BUT SKIN AND MESOTHELIOMA	58	0.65	76	0.74	18	1.28	24	0.95	29	0.77	5	0.90
HEAD AND NECK	2	0.51	2	0.44	0	0.00	0	0.00	2	1.20	0	0.00
ORAL CAVITY	1	1.07	1	0.93	0	0.00	0	0.00	1	2.53	0	0.00
PHARYNX	1	1.14	1	0.89	0	0.00	1	2.67	0	0.00	0	0.00
LARYNX	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00
ESOPHAGUS	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.46	-0.07
STOMACH	1	1.00	1	0.86	0	0.00	1	2.36	0	0.00	0	0.00

**THYROID**  
**POOL ARTIUM 1976-2010, UOMINI:**

Numero di soggetti vivi all'inizio dell'intervallo, anni-persone a rischio (PY), numero di secondari osservati (O), rapporto standardizzato di incidenza (SIR) ed eccesso assoluto di rischio (EAR) x 1000 pazienti per sede di secondo tumore e periodo di follow-up.

**THYROID**  
**POOL ARTIUM 1976-2010, UOMINI:**

Numero di soggetti vivi all'inizio dell'intervallo, anni-persone a rischio (PY), numero di secondari osservati (O), rapporto standardizzato di incidenza (SIR) ed eccesso assoluto di rischio (EAR) x 1000 pazienti per sede di secondo tumore e periodo di follow-up.

**FIRST CANCER SITE**  
**THYROID**

Number of subjects alive at the beginning of the interval, person-years at risk (PY), number of Observed (O) second cancers, Standardized Incidence Ratio (SIR) and Excess Absolute Risk (EAR) x 1000 cancer patients by second cancer site and follow-up period.

SECOND CANCER SITE	>2 months		12-59 months		60-119 months		>120 months		>2 months		>2 months	
	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	EAR	EAR
ALL SITES, BUT SKIN AND THYROID	417	1.22	450	1.27	33	3.01	48	1.03	184	1.46	55	1.05
HEAD AND NECK	11	0.65	12	0.68	1	1.80	3	1.26	4	0.52	2	0.79
ORAL CAVITY	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00
PHARYNX	1	0.24	1	0.24	0	0.00	0	0.00	0	0.00	0	0.00
LARYNX	10	1.15	11	1.22	1	3.44	3	2.42	3	0.75	2	0.91
ESOPHAGUS	3	0.79	4	1.03	1	8.09	0	0.00	3	1.75	0	0.00
STOMACH	25	1.40	25	1.36	0	0.00	3	1.19	10	1.23	10	2.49
COLON RECTUM	45	1.19	55	1.15	0	0.00	8	1.30	22	1.06	19	1.56
COLON	41	1.31	41	1.27	0	0.00	6	1.45	15	1.07	14	1.69
RECTUM	14	0.94	14	0.91	0	0.00	2	0.98	7	1.03	5	1.29
LIVER	12	0.86	13	0.90	1	2.22	0	0.00	6	0.95	4	1.11
GALLBLADDER	3	0.93	3	0.90	0	0.00	1	2.27	0	0.00	2	2.40
PANCREAS	7	0.77	8	0.85	1	3.47	0	0.00	5	1.22	0	0.00
LUNG	54	0.94	69	1.17	15	7.94	6	0.76	23	0.88	16	1.09
SOFT TISSUE	6	0.86	8	1.11	2	9.67	0	0.00	4	1.28	2	1.09
SKIN MELANOMA	6	3.12	6	3.03	0	0.00	1	3.99	2	2.33	3	5.95
MESOTHELIOMA	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00
KAPPOSI-SARCOMA	5	3.36	5	3.25	0	0.00	0	0.00	3	4.45	1	2.59
BONE	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00
BREAST	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00
PROSTATE	87	1.34	89	1.33	2	10.2	7	0.83	43	1.48	27	1.57
TESTIS	2	1.09	3	1.59	1	16.43	1	3.63	1	1.15	0	0.00
KIDNEY AND RENAL PELVIS	34	2.78	37	2.94	3	7.96	5	3.07	13	2.36	11	3.44
BLADDER AND URINARY TRACT	40	1.09	40	1.05	0	0.00	5	0.99	19	1.14	11	1.16
URINARY BLADDER	39	1.10	39	1.07	0	0.00	5	1.03	19	1.19	10	1.09
URINARY TRACT	1	0.70	1	0.68	0	0.00	0	0.00	0	0.00	1	2.68
BRAIN AND CENTRAL NERVOUS SYSTEM	11	2.19	11	2.12	0	0.00	0	0.00	7	3.06	3	2.32
THYROID	1	0.33	7	2.27	6	65.48	1	2.44	0	0.00	0	0.00
HODGKIN LYMPHOMA	2	1.46	2	1.41	0	0.00	1	4.92	0	0.00	1	2.90
NON-HODGKIN LYMPHOMA	15	1.33	17	1.46	2	5.63	1	0.65	8	1.57	3	1.02
MYELOMA	6	1.39	7	1.58	1	7.17	1	1.71	2	1.03	2	1.78
LEUKAEMIAS	12	1.56	12	1.51	0	0.00	2	1.86	4	2.02	4	2.02
LYMPHOID LEUKAEMIAS	5	1.34	5	1.30	0	0.00	1	1.91	0	0.00	2	2.10
MYELOID LEUKAEMIAS	7	1.99	7	1.92	0	0.00	1	2.06	3	1.88	2	2.18
OTHER LEUKAEMIAS	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00
OTHER AND ILL DEFINED SITES	21	1.25	24	1.39	3	5.47	3	1.30	5	0.66	9	2.07


Epidemiol Prev 37 (4-5) Suppl 1:1-152

► Ulteriori dati disponibili sul sito: [www.registri-tumori.it](http://www.registri-tumori.it)



**Legend:**  
 O Observed cases  
 SIR Standardized incidence ratio  
 EAR Excess absolute risk  
 Incidenza osservata  
 Rapporto standardizzato di incidenza  
 Eccesso assoluto di rischio





Login utente

Nome utente: \*


Password: \*

Accedi

Richiedi nuova password

Associazione Italiana Registri Tumori

HOME CERCA CHI SIAMO CONVEGNI AIRTUM REDAZIONE PRIVACY STAMPA



Home

### Collaborazioni

Qui trovate le monografie prodotte in collaborazione con altre associazioni, reti e/o istituti.

I numeri del cancro in Italia - 2015  
 Pubblicazione frutto della collaborazione AIOM-AIRTUM

I numeri del cancro in Italia - 2014  
 Pubblicazione frutto della collaborazione AIOM-AIRTUM

I numeri del cancro in Italia - 2013  
 Pubblicazione frutto della collaborazione AIOM-AIRTUM

I numeri del cancro in Italia - 2012  
 Pubblicazione frutto della collaborazione AIOM-AIRTUM

Home Page

I Registri tumori

AIRTUM

Numeri come  
Notizie

Banca Dati AIRTUM

Progetti AIRTUM

Formazione

Pubblicazioni **NEW**

- Anticipazioni
- Monografie AIRTUM
- Manuali
- Collaborazioni



### In primo piano


Corso AIRTUM per operatori dei RT  
 12-13 ottobre 2016  
 Salerno



Programma e scheda d'iscrizione del corso "Come registrare i mesoteliomi ed analizzare i dati"

23 settembre 2016,  
 Reggio Emilia

Il nuovo corso  
 FAD AIRTUM 2016



Legge di istituzione

## Prevalence

Prevalence of diagnosis for years (proportions for 100000, head full (absolute number and proportion), Male, age (0-99))

Cancer	2-year	5-year	10-year	15-year	20-year	Total
All sites but skin non melanoma	9519	1877.7	2783.9	3255.2	3511.5	29477.3
Head and neck	52.4	110.9	184.3	235	271.2	25417
Tongue	5.8	10.4	16	19.1	21	1791
Throat	6.6	12.1	18.3	22.1	24.2	2076
Salivary gland	2.4	4.8	7.7	9.2	10.9	1159
Oropharynx	4.4	8.2	12.4	14.7	16	1336
Nasopharynx	2.1	4.1	6.2	7.6	8.7	833
Hypopharynx	2.7	5	7.8	8.8	9.3	761

## Survival

5-year age-standardised relative survival (All sites but skin non melanoma)

Year	1990-1992	1993-1995	1996-1998
All sites but skin non melanoma	39 [36.39]	42 [42.43]	47 [46.4]
Salivary Gland	47 [37.57]	49 [39.59]	56 [47.6]
Oesophagus	7 [5.9]	10 [8.13]	9 [7.11]
Stomach	25 [24.26]	28 [27.30]	30 [28.3]
Small Intestine	38 [29.47]	39 [30.47]	41 [33.58]



## Incidence and mortality

Incidence (2005) All sites but skin non melanoma: Male

Age-specific rates per 100,000 Italy (2005) Male

Cancer	Total	0	5	10	15	20	25	30	35	40	45
All sites but skin non melanoma	258454	22.4	13.8	15.4	25.1	41.0	55.3	67.5	89.7	1314	1608
Head and neck	1254	0.1	0.1	0.3	0.7	0.9	1.2	1.5	4.3	100	100
Tongue	1381	-	0.1	-	0.2	0.2	0.4	1.1	1.8	38.3	57
Throat	523	-	0.1	-	0.1	0.2	0.3	0.3	0.3	570.3	406.9
Salivary gland	1115	-	-	-	0.3	0.2	0.3	0.3	0.4	-0.4	-0.3
Oropharynx	521	0.1	-	0.3	0.3	0.2	0.3	0.4	0.4	810	587
Hypopharynx	745	-	-	0.1	0.0	0.0	0.0	0.0	0.0	100	100
Hypopharynx	2388	-	-	0.1	0.2	0.3	0.3	0.3	0.3	18.6	18.6
Stomach	12212	-	-	0.1	0.1	0.1	0.1	0.1	0.1	35.2	135.4
Small intestine	895	-	-	0.1	0.1	0.1	0.1	0.1	0.1	263.7	-1.8
Colon, rectum and anus	24106	-	0.1	0.1	0.1	0.1	0.1	0.1	0.1	69	21
Colon, rectum and anus	35154	-	-	0.1	0.1	0.1	0.1	0.1	0.1	77 [76-78]	59 [58-61]
Rectum and anus	11148	-	-	0.1	0.2	0.2	0.2	0.2	0.2	-	-
Liver	10733	0.4	0.2	-	0.3	0.2	0.2	0.2	0.2	-	-
Gallbladder	2577	-	-	0.1	-	-	-	-	-	-	-
Pancreas	7022	-	-	0.1	-	-	-	-	-	-	-
Blas cavities	422	-	-	0.1	-	-	-	-	-	-	-
Larynx	6310	-	-	0.1	-	-	-	-	-	-	-
Lung, bronchus, trachea	39289	0.1	-	0.2	-	-	-	-	-	-	-
Bladder	474	0.9	0.8	1.9	2.2	2.2	2.2	2.2	2.2	2.2	2.2
Bladder	5875	0.1	-	0.4	-	-	-	-	-	-	-
Neonoma of skin	1792	-	-	-	-	-	-	-	-	-	-
Neonoma of skin	9/4	-	-	-	-	-	-	-	-	-	-
Consecutive issue	1477	1.7	1.1	0.9	0.8	1.1	0.9	1.1	0.9	1.1	0.9
Penis	539	-	-	0.1	0.1	0.0	0.1	0.0	0.1	0.0	0.1
Prostate	52553	0.1	0.1	0.1	0.0	0.0	0.1	0.0	0.1	0.0	0.1
Testis	2456	0.2	0.1	0.3	3.5	12.4	17.8	17.6	13.8	13.8	13.8
Kidney and urinary organs	10076	1.7	0.4	0.2	0.3	0.5	1.0	2.5	4.8	8.8	8.8
Bladder	25007	0.1	0.1	0.1	0.3	0.7	1.7	2.6	4.9	9.9	20.0
Bladder	323	1.3	0.1	-	0.1	0.1	0.1	0.3	0.4	0.4	0.5
Bladder	4003	2.8	2.5	1.7	2.0	2.4	3.3	4.3	4.3	4.3	4.3

### Cancer in Italy

Logical cancer measures of the 3 major cancers recorded by access to summary data with graphic and tabulation has the copyright of the materials on the Website. The data you may use it "as is" but must cite the corresponding registry or indirectly, a collection, database or directory without with the Section of Cancer Information (CIN) at IARC. We recommend that you first read the section: The ITACAN database. of Cancer Registries (<http://www.registri-tumori.it>).


of Cancer Registries, 2012




# The need for a rapid and comprehensive adoption of the revised European standard population in cancer incidence comparisons

Emanuele Crocetti, Tadek Dyba, Carmen Martos, Giorgia Randi, Roisin Rooney and Manola Bettio

Fig. 1



Pyramids of the weight (in thousands of individuals) of each age class in the European standard population (ESP) and in the revised European standard population (RESP).



**INCAIL**

**QUINTO RAPPORTO**




**Tabella 30** Tassi grezzi di incidenza (per 100.000) di mesotelioma maligno certo, probabile e possibile per sede anatomica e genere. Italia 2009 - 2011, con riferimento alle sole Regioni con dati di incidenza


Sede	Genere	2009	2010	2011
Pleura	Uomini	3,68	3,55	3,70
	Donne	1,27	1,39	1,34
Peritoneo	Uomini	0,19	0,24	0,18
	Donne	0,11	0,14	0,13
Pericardio	Uomini	0,02	0,004	0,004
	Donne	-	0,003	0,003
Tunica Vaginale Testicolare	Uomini	0,01	0,01	0,01

**Tabella 33** Tassi standardizzati di incidenza (per 100.000) di mesotelioma maligno certo, probabile e possibile per sede anatomica e genere. Italia 2009 - 2011, con riferimento alle sole Regioni con dati di incidenza


Sede	Genere	2009	2010	2011
Pleura	Uomini	3,69	3,31	3,64
	Donne	1,26		
Peritoneo	Uomini	0,18		
	Donne	0,11		
Pericardio	Uomini	0,02		
	Donne	-		
Tunica Vaginale Testicolare	Uomini	0,01		

**Figura 32** Tassi specifici di incidenza (per 100.000) di mesotelioma maligno della pleura (certo, probabile e possibile) per età (linea spezzata) e numero di casi. Italia, 2008 - 2011. Uomini e donne, con riferimento alle sole Regioni con dati di incidenza







**Figura 33** Tassi specifici di incidenza (per 100.000) di mesotelioma maligno della pleura (certo, probabile e possibile) per età. Italia, 1993 - 2011. Uomini, con riferimento alle sole Regioni con dati di incidenza



Mapa 8

Distribuzione comunale dei tassi grezzi di mesotelioma pleurico negli uomini.  
Periodo di diagnosi 1993 - 2012.  
Diagnosi di mesotelioma certo, probabile o possibile





# Conclusioni e proposte



- Confronto limitato ai dati elaborati e disseminati sia da AIRTum che da ReNAM



## Analisi dati

	Sede (topog.)	Incidenza							Sopravv			
		Casi oss.	Tassi			Pop std.	Analisi spaziali (1)	Trend tempor.	Coorti o MAPC (2)	Assol.	Relat.	Trend tempor.
			Grezzi	Std.	Età- spec.							
<b>Standard nazionali</b>												
Airtum (3)	Tutte	Sì	Sì	Sì	In grafico	Euro	Per registro	APC (4) e in grafico		Sì	Sì	
ReNaM (5)	Per sede	Sì	Sì	Sì	In grafico	Italia 2010	Per comune (6)	In grafico	Grafico età- spec.			
<b>Standard locali</b>												
RMM	Per sede	Sì	(7)	Sì	(7)	Euro27	Per distretto	Sì		Sì		

### Note

- (1) Massimo livello di disaggregazione geografica nell'analisi
- (2) Tassi per coorte di nascita o modelli età-periodo-coorte (MAPC)
- (3) Banca dati AIRTUM: ITACAN
- (4) APC: cambiamento percentuale annuale negli ultimi 5 anni
- (5) Rapporti ReNaM, in particolare 4 e 5 rapporto
- (6) Comune di residenza alla diagnosi
- (7) Sono stimati ma non pubblicati

# Conclusioni e proposte



- Statistiche distinte per sede anatomica
- Adozione della Revised European standard population
- Importanza della distribuzione spaziale per piccole aree (comunale)
- Importanza delle tendenze temporali dei tassi di incidenza età-specifici